Novo Nordisk invests billions of dollars in post-semaglutide future
In the coming years, Novo Nordisk will increase its R&D costs at a higher rate than future top line growth to find one or more successors for the current growth engine semaglutide once its patent expires. Although Novo’s faith in its scientists is strong, external acquisitions remain an option, says CFO Karsten Munk Knudsen.
by MIKKEL AABENHUS HEMMINGSEN & ANDREAS LØNSTRUP, translated by daniel pedersen
Novo Nordisk has been riding a wave of success in recent years, due in large part to GLP 1 analog semaglutide – but now is not the time to slack off on the work to bring new drugs to market, says Novo Nordisk’s CFO, Karsten Munk Knudsen at a teleconference on Wednesday in connection with the release of Novo’s 2021 financial figures.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Disappointing phase I results halt Novo's Dutch acquisition
For subscribers
